Hepius Therapeutics

Hepius Therapeutics is a preclinical-stage biotechnology company focused on developing next-generation precision immuno-oncology therapeutics. Utilizing its patient-centric reverse translational medicine platform, the company identifies novel targets and resistance mechanisms directly from clinical patient data. Hepius Therapeutics leverages a proprietary T-cell receptor (TCR) discovery and engineering platform to target intracellular tumor antigens, alongside developing antibody-drug conjugates (ADCs) and radiopharmaceuticals. Its lead programs include HP-004, an ALPP/ALPPL2-targeting ADC, and HP-002, a TCR-based therapeutic targeting PRAME for solid tumors.